Clinical Trial Update: Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of Sanofi Pasteur's lipid nanoparticle-encapsulated mRNA vaccine candidate for human metapneumovirus and respiratory syncytial virus in adults a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Sanofi mRNA vaccine candidate (hMPV/RSV) (mRNA vaccine encapsulated in lipid nanoparticle formulation targeting human metapneumovirus and respiratory syncytial virus)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING